efficacy and safety of dabigatran(paradxa) in pediatric thromboembolism Referring to Amir Kabir Hospital in Arak

Phase 3

Recruiting

• Conditions: children-thromboemboli.; Embolism and thrombosis of other arteries

• Registration Number: IRCT20180711040431N1
• Lead Sponsor: Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 14 January 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Informed consent
Children under 18 years
Affected by Thromboembolism

Exclusion Criteria

Having other blood disorders

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bleeding frequency. Timepoint: In the first month, each week and then every month, Primary outcomes are checked. Method of measurement: Interview with patient or family.;Recurrent thromboembolism. Timepoint: In the first month, each week and then every month, they are checked. Method of measurement: History and clinical examination and, if needed, imaging.;Liver and kidney function during drug use. Timepoint: In the first month, each week and then every month, they are checked. Method of measurement: History and clinical examination and, if needed, Liver Function Tests.